Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nipro's other current liabilities for the quarter that ended in Mar. 2026 was 円64,640 Mil.
Nipro's quarterly other current liabilities
increased
from Sep. 2025 (円53,799 Mil) to Dec. 2025 (円62,535 Mil) and
increased
from Dec. 2025 (円62,535 Mil) to Mar. 2026 (円64,640 Mil).
Nipro's annual other current liabilities
increased
from Mar. 2024 (円57,605 Mil) to Mar. 2025 (円61,216 Mil) and
increased
from Mar. 2025 (円61,216 Mil) to Mar. 2026 (円64,640 Mil).
Nipro Other Current Liabilities Related Terms
Nipro Other Current Liabilities Historical Data
* Premium members only.
The historical data trend for Nipro's Other Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.
What does a Other Current Liabilities of 円64,640 Mil mean?
Nipro (TSE:8086) has a Other Current Liabilities of 円64,640 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Nipro.
Is Nipro's Other Current Liabilities too high?
Nipro's current Other Current Liabilities is 円64,640 Mil. Overall, Nipro has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nipro's Other Current Liabilities compare to ISRG and BDX?
Nipro's Other Current Liabilities of 円64,640 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Nipro. Nipro's current Other Current Liabilities is 円64,640 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nipro stock overvalued right now?
Based on GuruFocus' analysis, Nipro (TSE:8086) is currently considered Fairly Valued. The stock's GF Value™ is 円1,465.84, compared to a current price of 円1,570.00 — trading 7.1% above its estimated fair value. The current Other Current Liabilities is 円64,640 Mil. Nipro's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Nipro (TSE:8086), the current Other Current Liabilities is 円64,640 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nipro (TSE:8086) Overvalued in 2026?
Based on GuruFocus' analysis, Nipro stock appears to be overvalued.
The current stock price of 円1,570.00 is trading 7.1% above its estimated GF Value™ of 円1,465.84.
GuruFocus considers Nipro to be Fairly Valued.
Key valuation signals for TSE:8086:
Other Current Liabilities: 円64,640 Mil
GF Value™: 円1,465.84 vs. price of 円1,570.00 (7.1% above fair value)
No single metric tells the full story. See the TSE:8086 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.
72GF Score
Get the complete analysis for TSE:8086
Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:8086 has been successfully added to your 
